FDA Approves First At-Home Brain Stimulation Device for Depression Treatment
核心洞察
The FDA approved Flow FL-100 (搜索), the first at-home transcranial direct current stimulation device cleared in the US for treating moderate to severe depression in adults.
The approval was supported by the Empower study, a remote, double-blind, placebo-controlled trial with 174 patients showing statistically significant improvements in depression scores.
The headset device can be used alone or with medication and directly targets brain function to address depression symptoms.
The FDA has approved Flow FL-100 (搜索), marking a significant milestone as the first at-home transcranial direct current stimulation (tDCS) medical device cleared in the United States for treating moderate to severe depression in adults. The device can be used either as a standalone treatment or in combination with medication, offering patients a new therapeutic option that directly targets brain function.
Clinical Evidence Supporting Approval
The regulatory approval was supported by results from the Empower study, a remote, double-blind, placebo-controlled trial involving 174 patients. The study demonstrated statistically significant improvements in Hamilton Depression Rating Scale scores with active treatment compared to placebo, providing robust evidence for the device's efficacy in treating depression.
The headset device is designed to address depression by directly targeting brain function through transcranial direct current stimulation, a non-invasive neurostimulation technique that applies low-intensity electrical currents to specific brain regions.
Global Experience and Market Presence
Flow FL-100 (搜索) has been available in several countries since 2019, providing Flow Neuroscience (搜索) with extensive real-world experience before entering the US market. This international track record has contributed to the understanding of the device's safety and efficacy profile across diverse patient populations.
Treatment Innovation
The approval represents a novel approach to depression treatment, offering patients an at-home neurostimulation option that can complement existing therapeutic strategies. By enabling home-based treatment, the device addresses accessibility challenges often associated with traditional neurostimulation therapies that require clinical visits.
The device's ability to function as either monotherapy or adjunctive treatment provides flexibility for healthcare providers in developing personalized treatment plans for patients with moderate to severe depression. This versatility is particularly significant given the heterogeneous nature of depression and the need for individualized therapeutic approaches.